aiv infeqcia/SidsiT avadmyofTa mkurnaloba da movla (klinikuri ...
aiv infeqcia/SidsiT avadmyofTa mkurnaloba da movla (klinikuri ...
aiv infeqcia/SidsiT avadmyofTa mkurnaloba da movla (klinikuri ...
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
igulisxmeba im medikamentebis kombinacia, romlebic SesaZloa muSaobdes<br />
an virusi maT mimarT iyos nawilobriv rezistentuli. yvela reJimi meore<br />
rigis Semdgom garTulebulia <strong>da</strong> moiTxovs arT-codnis maRal dones <strong>da</strong><br />
unar-Cvevebs. genotipuri rezistentobis testis monacemebi am situaciaSi<br />
aucilebelia. zogierT SemTxvevebSi ga<strong>da</strong>rCenis Terapiis <strong>da</strong>wyebamde<br />
umjobesia ramodenime TviT moc<strong>da</strong>, Tumca es strategia SesaZloa iyos<br />
saSiSi, kerZod, Tu CD4 ujredebis ricxvi <strong>da</strong>balia.<br />
o Tu SesaZlebelia, un<strong>da</strong> CaerTos ori medikamentis efeqturi<br />
kombinacia mag; SeWris inhibitori enfurvitidi (ENF) (96) (CIII),<br />
romelic iniSneba 2-jer dReSi kanqveSa aplikaciis saxiT <strong>da</strong> axali<br />
pi TPV (97,90) (CIII), an axali pi TCM114 (99,100) (CIII).<br />
o TPV- genetikuri barieri ufro maRalia, vidre LPV/r <strong>da</strong> monacemebi<br />
gviCveneben mis efeqturobas am ukanasknelTan Se<strong>da</strong>rebiT. dRevandel<br />
dRes TPV gamoiyeneba mxolod ga<strong>da</strong>rCenis Terapiis reJimebSi.<br />
o sxva SesaZleblobaa ori pi kombinacia (102-104) (CIII), gamonaklisia<br />
TPV, romelic ar un<strong>da</strong> gamoviyenoT sxva pi–sTan kombinaciaSi.<br />
4.7. mkurnalobis <strong>da</strong>gegmili Sewyveta<br />
bevri ewinaaRmdegeba arT <strong>da</strong>gegmil Sewyvetas, Tumca <strong>da</strong>sabuTeba<br />
SesaZlebelia. mag. CD4>500 mm 3 mudmivi done <strong>da</strong> virusis supresia mravali<br />
wlebis ganmavlobaSi abrkolebs oportunistuli infeqciebis<br />
ganviTarebas. mkurnalobis <strong>da</strong>gegmili Sewyveta, mkurnalobis reJimis<br />
araadeqvaturad <strong>da</strong>cvis SemTxvevaSi, Tavi<strong>da</strong>n agvacilebs rezistentuli<br />
Stamebis ganviTarebas. mkurnalobis Sewyvetis Semdeg CD4 limfocitebis<br />
ricxvi Camodis pre-arv Terapiis donemde , amdenad aucilebelia pirveli<br />
sami Tvis ganmavlobaSi CD4 limfocitebis ricxvis monitoringi. zogierT<br />
pacientSi limfocitebis ricxvi >350 mm 3 <strong>da</strong> <strong>da</strong>bali virusuli <strong>da</strong>tvirTva<br />
(1000-5000 asli/ml) Tveebisa <strong>da</strong> wlebis ganmavlobaSia SenarCunebuli.<br />
mkurnalobis <strong>da</strong>gegmili Sewyvetis sargebelze arasakmao informaciis<br />
arsebobis gamo janmos mier igi ar aris rekomendebuli.<br />
5.<strong>aiv</strong> inficirebul pacientTa <strong>klinikuri</strong> monitoringi<br />
mas Semdeg rac a<strong>da</strong>mians <strong>da</strong>esmeba <strong>aiv</strong> infeqciis diagnozi is<br />
uzrunvelyofili un<strong>da</strong> iyos monitoringiTa <strong>da</strong> movliT.<br />
5.1. laboratoriuli indikatorebi arT <strong>da</strong>wyebamde<br />
CD4 ujredebis ricxvi<br />
o gaimeoreT yovel 6 TveSi, Tu aris amouxsneli Sedegebi (CD4<br />
ujredebis swrafi <strong>da</strong>qveiTeba an oportunistuli infeqciebis<br />
ganviTareba);<br />
o Tu mimdinareobs msjeloba arT <strong>da</strong>wyebaze (CD4 ujredebi tolia<br />
an
Change language